Ventyx Rises on Eli Lilly Talks, Mobileye, Strategy Rises
Description
On this episode of Stock Movers:
- Eli Lilly (LLY) is in advanced talks to acquire Ventyx Biosciences (VTYX) for more than $1 billion to expand its work in immunology, according to a report in the Wall Street Journal.Ventyx shares rose 60% at 4:38 p.m. in US postmarket trading to $16.13. At that price, the San Diego-based biotech that specializes in drugs for inflammatory diseases like Crohn’s and rheumatoid arthritis is set to add $433.9 million to its market capitalization.
- Self-driving car systems company Mobileye Global (MBLY) is acquiring Israeli startup Mentee Robotics in a cash-and-stock deal valued at $900 million, as it looks to develop humanoid robots. The deal comprises $612 million in cash and as many as 26,229,714 shares of Mobileye Class A common stock, according to the company. It is expected to close in the first quarter of 2026.
- In a statement Tuesday, MSCI said it would maintain current index treatment for so-called digital asset treasury companies, including those where crypto holdings exceed 50% of total assets. That means Strategy — which holds over $60 billion in Bitcoin — will remain in the firm’s global benchmarks for now. Instead, MSCI will launch a “broader consultation” on how non-operating companies should be treated. Shares of Strategy rose around 5% in after-market trading. The stock had slumped almost 60% in the past year.
See omnystudio.com/listener for privacy information.




